On Tuesday, July 8, 2025, the 8th Greater Tokyo Biocommunity (GTB) Working-Level Meeting was successfully held in a hybrid format, combining both in-person and online participation. The venue for the in-person session was Mitsui Link-Lab Shinkiba 2, located in the Nihonbashi area-one of the eight GTB Innovation Promotion Hubs. A total of 124 participants attended, with 89 joining on-site and 35 online. Venue; Mitsui Link-Lab Shinkiba 2 The 8th GTB Working-level Meeting Greetings from the Chairman of GTB Council Prior to the meeting, a guided tour of the Mitsui Link-Lab Shinkiba 2 facility was organized thanks to the generous support of LINK-J and Mitsui Fudosan. The tour, attended by 76 […]

The Bioeconomy Strategy formulated in 2019 was updated at the Integrated Innovation Strategy Promotion Council held on June 3, 2024. In this strategy, in order to contribute to both sustainable economic growth and solving various problems, the following five market areas were identified:   (1) Biomanufacturing / bio-derived products (2) Sustainable primary production systems (3) Large-scale buildings utilizing wood and smart forestry (4) Industries related to biopharmaceuticals, regenerative medicine, and cell and gene therapies (5) Lifestyle improvement healthcare and digital health   The goal is to create a 100 trillion yen market in Japan and overseas by 2030.   For each market, the plan sets out a vision for 2030

A GTB survey compiled a list of private investment topics for each GTB bio-innovation promotion centre. It found that the total amount for the entire Tokyo region amounts to JPY 500 billion/2 years, mainly in infrastructure development, start-up funding and IPOs.

The JBA survey found that 12 of the 17 certified biopharmaceutical manufacturing sites have manufacturing and head office functions in the Tokyo area. Others, such as biofoundries.